RT Journal Article
SR Electronic
T1 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.10.20169912
DO 10.1101/2020.08.10.20169912
A1 Buonsenso, Danilo
A1 Valentini, Piero
A1 De Rose, Cristina
A1 Pata, Davide
A1 Sinatti, Dario
A1 Speziale, Domenico
A1 Ricci, Rosalba
A1 Carfì, Angelo
A1 Landi, Francesco
A1 Sanguinetti, Maurizio
A1 Sali, Michela
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.08.10.20169912.abstract
AB Wheather children are easily susceptible to SARS-CoV-2 infection is still a debated question and a currently a hot topic, particularly in view of important decisions on school opening. For this reason, we decide to describe preliminary data showing the prevalence of anti-SARS-CoV-2 IgG in children with known household exposure to SARS-CoV-2.Our report shows that household transmission of SARS-CoV-2 is high in both adults and children, with similar rates of SARS-CoV-2 IgG in all age groups, including the younger children. A total of 44 out of 80 household contacts (55%) of index patients had anti SARS-CoV-2 IgG. In particular, 16 (59,26%) adult partners had IgG antibodies compared with 28 (52,83%) of pediatric contacts (P > 0.05). Among the pediatric population, children ≥ 5 years of age had similar probability of having SARS-CoV-2 IgG (21/39, 53.8%) compared with those < 5 years (7/14, 50%) (P > 0.05). Adult partners and children also had a probability of having SARS-CoV-2 IgG. Interestingly, 35.7% of children and 33.3% of adults with SARS-CoV-2 IgG were previously diagnosed as COVID-19 cases.Since this evidence of high rate of IgG in children exposed to SARS-CoV-2 has public health implication, with this comment we highlight the need of establishing appropriate guidelines for school opening and other social activities related to childhood.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialnot registered for organizational proceduresFunding Statementnothing to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by the Ethic Committee of the Fondazione Policilnico Universitario A. Gemelli IRCCS, Rome, italy (ID 3078)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesavailable upon request